Two genome-wide association studies for testicular cancer report associations at three new loci, including two candidate genes previously implicated in testicular development, KITLG (ligand for the receptor tyrosine kinase) and SPRY4 (sprouty 4). These studies are notable for the high effect sizes detected and the biological plausibility of the candidate genes.
Every investigator conducting a genome-wide association study (GWAS) has a moment of pause before looking at their newly minted results. After all the effort to collect phenotypes and biospecimens, generate genotypes and conduct association analyses, there is a moment of truth when one wonders whether it has been worth it. On pages 811 and 807 of this issue, Kanetsky et al. 1 and Rapley et al. 2 report independent GWAS for susceptibility to testicular germ cell tumors (TGCT). In this case, the investigators' hard work has certainly paid off. Together, they report three new robust and replicated associations with risk for TGCT, including two reported in both studies, that provide biologically plausible candidate genes (KITLG and SPRY4). Rapley et al. 2 identified a third locus, in an intron of BAK1, a gene that promotes apoptosis. These studies place the notion of a genetic predisposition to this cancer on firmer ground (Fig. 1) .
TGCT is the most commonly diagnosed cancer in men between ages 15 and 44. A number of lines of evidence have pointed toward a strong hereditary component for TGCT 3 . These include a substantially higher risk for brothers and fathers, although extended pedigrees with multiple cases are unusual 4 . Twin studies have also demonstrated very high risk 5 . Although a genetic predisposition to TGCT was previously expected, it took these GWAS studies to definitively identify the first set of genetic variants associated with susceptibility to this cancer.
The current studies are notable for the high estimated effect sizes of the associated genetic variants; the estimated per-allele odds ratio for an associated locus on chromosome 12 (in the region of KILTG) is the highest of any observed for a cancer phenotype to date, well above 2.0. Although more work lies ahead to map, investigate and eventually develop the clinical utility of these genetic markers, the other good news here is that the new associations point toward regions harboring excellent candidate genes for further study.
Finding plausible genes
The two studies reported here were each well powered to detect variants with an effect size as large as that for the chromosome 12 locus, so it is not surprising that these were discovered by each group. In the smaller of the two studies, Kanetsky et al. 1 scanned 277 cases and compared them to 919 available controls, with replication in an additional cohort. The Rapley et al. study 2 was slightly better powered, with 730 cases and 1,435 controls, including familyloaded cases, and again replication in an additional population. The association maps to a locus harboring the KITLG gene (known as either stem cell or Steel factor), which encodes the ligand for the membrane receptor tyrosine kinase, c-KIT, extensively investigated in multiple cancers, and also a key actor in primordial germ cell development 6 . Indeed, abundant corroborative data link somatic and germ cell mutations in the KIT/KITLG system to pathogenesis of testicular cancer and infertility in mice and men, making KITLG a very promising candidate gene (Fig. 1) . Still, as is true for all GWAS associations, one must invoke a healthy skepticism and consider the possibility that the association could work through a mechanism unrelated to this gene. The interpretation of the new association on n e w s a n d v i e w s chromosome 5 is slightly different, given the smaller (and more typical) effect size, with an estimated per allele odds ratio of 1.3. The current studies were not well powered to detect effects of this size, and so the independent finding of this association by both groups seems a bit more lucky.
This is just the beginning
Once a genome-wide significant association signal is conclusively established, the next steps forward are often long and arduous. The fine-mapping of the newly associated loci is essential, and examining the variants in different populations can be informative. Such follow-up studies are needed to resolve the nature of the association, and resolve both common and rare variants that may be lurking in these regions. Further studies should also include examining the associated variants in model organisms, tissue samples and in vitro studies.
Another daunting challenge will be to dissect the signals by molecular or histologic subtypes. The two TGCT studies here included combined seminoma and nonseminoma tumors, primarily to achieve adequate power to detect a main effect. Although the findings for risk of TGCT overall were significant, the subtype analyses was underpowered and will require substantially larger datasets.
Nongenetic risk factors associated with testicular cancer should also be explored to refine our understanding based on exposures and prior conditions (for example, cryptorchidism, testicular atrophy and male infertility) that are known to increase risk for TGCT. The opportunity to explore early exposures, either prepubertal or in utero, and gene-environment interactions is rich, primarily because of the young age of onset of TGCT.
Recently, genome-wide association studies have come under criticism for failing to adequately explain the heritability underlying a spectrum of human diseases and traits 8 . This is somewhat surprising, in light of the remarkable discovery of hundreds of new loci for human diseases and traits using the GWAS approach 9 . We should also consider that we are still early in the discovery phase, and it is daunting to assess the actual contribution of genetic variation to disease until we know more about the spectrum of the contributing genetic variants as well as the environmental risk factors. Further, we need to be cautious about quickly transitioning the newly discovered loci to use in tools for clinical risk assessment, often in the same studies, which may not necessarily be well designed to address the question of risk 10 . Indeed, we have a long way to go to make sense of the high marks garnered by GWAS this far. volume 41 | number 7 | july 2009 | nature genetics
TET2 mutations in myelodysplasia and myeloid malignancies

Charles G Mullighan
The genetic basis of myelodysplasia has long been enigmatic, with few common targets of mutation known. a new study reports common mutations in the TET2 gene in myelodysplasia and related myeloid malignancies, suggesting that TET2 has an important role in hematopoiesis and in the pathogenesis of this disease. Myelodysplasia (MDS) is a hematological malignancy characterized by ineffective hematopoiesis and an increased risk of acute myeloid leukemia (AML). Identifying the genetic variants contributing to the pathogenesis of MDS has been difficult, at least using low-resolution and candidate-gene approaches. A study by Joop Jansen and colleagues on page 838 of this issue now identifies common recurring genetic alterations in the TET2 gene in MDS and related disorders 1 .
These findings represent an important advance on two fronts: providing the description of one of the first common mutations in MDS and identifying TET2 as a gene likely to have a key role in blood cell development.
The mystery of myelodysplasia
Understanding the biological basis of MDS is one of the greatest challenges facing hematology. MDS represents a group of clonal hematological disorders that share dysplastic hematopoiesis (cells of abnormal appearance in the bone marrow) and variable reduction in the number of circulating red blood cells, leukocytes and platelets. Individuals with MDS develop symptomatic anemia, infections and bleeding, and have an increased risk of developing AML. MDS commonly affects older individuals, and effective targeted therapies are lacking. Unlike acute leukemia, in which many recurring chromosomal translocations targeting key hematopoietic regulators have been identified, the genetic basis of MDS is poorly understood 2 . Gross chromosomal changes involving chromosomes 5, 7 and 8 (for example, 5q−/−5, 7q−/−7 and trisomy 8) are present in up to one quarter of individuals with MDS. This suggests that tumor suppressor genes are located on these chromosomes, and a recent RNA interference screen identified RPS14 as the disease gene in 5q-syndrome, a subtype of MDS characterized by defective erythroid maturation 3 . However, many individuals with MDS have no cytogenetic alteration 4 , and
